F-18-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Koo, Hye Ryoung | - |
dc.contributor.author | Park, Jeong Seon | - |
dc.contributor.author | Kang, Keon Wook | - |
dc.contributor.author | Cho, Nariya | - |
dc.contributor.author | Chang, Jung Min | - |
dc.contributor.author | Bae, Min Sun | - |
dc.contributor.author | Kim, Won Hwa | - |
dc.contributor.author | Lee, Su Hyun | - |
dc.contributor.author | Kim, Mi Young | - |
dc.contributor.author | Kim, Jin You | - |
dc.contributor.author | Seo, Mirinae | - |
dc.contributor.author | Moon, Woo Kyung | - |
dc.date.accessioned | 2022-07-16T05:42:07Z | - |
dc.date.available | 2022-07-16T05:42:07Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2014-03 | - |
dc.identifier.issn | 0938-7994 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/160502 | - |
dc.description.abstract | Objectives To determine whether a correlation exists between maximum standardized uptake value (SUVmax) on F-18-fluorodeoxyglucose positron emission tomography (FDG-PET) and the subtypes of breast cancer. Methods This retrospective study involved 548 patients (mean age 51.6 years, range 21-81 years) with 552 index breast cancers (mean size 2.57 cm, range 1.0-14.5 cm). The correlation between F-18-FDG uptake in PET/CT, expressed as SUVmax, and immunohistochemically defined subtypes (luminal A, luminal B, human epidermal growth factor receptor 2 (HER2) positive and triple negative) was analyzed. Results The mean SUVmax value of the 552 tumours was 6.07 +/- 4.63 (range 0.9-32.8). The subtypes of the 552 tumours were 334 (60 %) luminal A, 66 (12 %) luminal B, 60 (11 %) HER2 positive and 92 (17 %) triple negative, for which the mean SUVmax values were 4.69+/-3.45, 6.51+/-4.18, 7.44+/-4.73 and 9.83+/-6.03, respectively. In a multivariate regression analysis, triple-negative and HER2-positive tumours had 1.67-fold (P < 0.001) and 1.27-fold (P = 0.009) higher SUVmax values, respectively, than luminal A tumours after adjustment for invasive tumour size, lymph node involvement status and histologic grade. Conclusion FDG uptake was independently associated with subtypes of invasive breast cancer. Triple-negative and HER2-positive breast cancers showed higher SUVmax values than luminal A tumours. Key Points F-18-FDG PET demonstrates increased tissue glucose metabolism, a hallmark of cancers. Immunohistochemically defined subtypes appear significantly associated with FDG uptake (expressed as SUVmax). Triple-negative tumours had 1.67-fold higher SUVmax values than luminal A tumours. HER2-positive tumours had 1.27-fold higher SUVmax values than luminal A tumours. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.title | F-18-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Jeong Seon | - |
dc.identifier.doi | 10.1007/s00330-013-3037-1 | - |
dc.identifier.scopusid | 2-s2.0-84896706288 | - |
dc.identifier.wosid | 000332658100009 | - |
dc.identifier.bibliographicCitation | EUROPEAN RADIOLOGY, v.24, no.3, pp.610 - 618 | - |
dc.relation.isPartOf | EUROPEAN RADIOLOGY | - |
dc.citation.title | EUROPEAN RADIOLOGY | - |
dc.citation.volume | 24 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 610 | - |
dc.citation.endPage | 618 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Radiology, Nuclear Medicine & Medical Imaging | - |
dc.relation.journalWebOfScienceCategory | Radiology, Nuclear Medicine & Medical Imaging | - |
dc.subject.keywordPlus | INTERNATIONAL EXPERT CONSENSUS | - |
dc.subject.keywordPlus | FDG UPTAKE | - |
dc.subject.keywordPlus | NEOADJUVANT CHEMOTHERAPY | - |
dc.subject.keywordPlus | PRIMARY THERAPY | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | PET/CT | - |
dc.subject.keywordPlus | HIGHLIGHTS | - |
dc.subject.keywordPlus | RECURRENCE | - |
dc.subject.keywordPlus | GRADE | - |
dc.subject.keywordAuthor | Breast cancer | - |
dc.subject.keywordAuthor | PET | - |
dc.subject.keywordAuthor | FDG uptake | - |
dc.subject.keywordAuthor | Immunohistochemistry | - |
dc.subject.keywordAuthor | Subtype | - |
dc.identifier.url | https://link.springer.com/article/10.1007/s00330-013-3037-1 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.